UROGEN PHARMA LTD (URGN) Fundamental Analysis & Valuation

NASDAQ:URGN • IL0011407140

Current stock price

24.11 USD
-0.2 (-0.82%)
At close:
24.11 USD
0 (0%)
After Hours:

This URGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. URGN Profitability Analysis

1.1 Basic Checks

  • URGN had negative earnings in the past year.
  • In the past year URGN has reported a negative cash flow from operations.
  • URGN had negative earnings in each of the past 5 years.
  • In the past 5 years URGN always reported negative operating cash flow.
URGN Yearly Net Income VS EBIT VS OCF VS FCFURGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • With a Return On Assets value of -76.57%, URGN is not doing good in the industry: 67.83% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -76.57%
ROE N/A
ROIC N/A
ROA(3y)-59.44%
ROA(5y)-70.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
URGN Yearly ROA, ROE, ROICURGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K

1.3 Margins

  • Looking at the Gross Margin, with a value of 88.66%, URGN belongs to the top of the industry, outperforming 90.31% of the companies in the same industry.
  • In the last couple of years the Gross Margin of URGN has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for URGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y-0.62%
URGN Yearly Profit, Operating, Gross MarginsURGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100K -200K -300K -400K -500K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. URGN Health Analysis

2.1 Basic Checks

  • URGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, URGN has more shares outstanding
  • The number of shares outstanding for URGN has been increased compared to 5 years ago.
  • The debt/assets ratio for URGN is higher compared to a year ago.
URGN Yearly Shares OutstandingURGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
URGN Yearly Total Debt VS Total AssetsURGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • URGN has an Altman-Z score of -5.05. This is a bad value and indicates that URGN is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -5.05, URGN is not doing good in the industry: 64.15% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.05
ROIC/WACCN/A
WACC8.09%
URGN Yearly LT Debt VS Equity VS FCFURGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 4.01 indicates that URGN has no problem at all paying its short term obligations.
  • With a Current ratio value of 4.01, URGN perfoms like the industry average, outperforming 47.48% of the companies in the same industry.
  • URGN has a Quick Ratio of 3.65. This indicates that URGN is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.65, URGN perfoms like the industry average, outperforming 46.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.01
Quick Ratio 3.65
URGN Yearly Current Assets VS Current LiabilitesURGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. URGN Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 0.93% over the past year.
  • URGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.45%.
  • The Revenue has been growing by 56.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)0.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.5%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y19.48%
Revenue growth 5Y56.22%
Sales Q2Q%54.03%

3.2 Future

  • Based on estimates for the next years, URGN will show a very strong growth in Earnings Per Share. The EPS will grow by 31.85% on average per year.
  • URGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 52.71% yearly.
EPS Next Y62.75%
EPS Next 2Y54.63%
EPS Next 3Y41.5%
EPS Next 5Y31.85%
Revenue Next Year120.41%
Revenue Next 2Y94.11%
Revenue Next 3Y68.59%
Revenue Next 5Y52.71%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
URGN Yearly Revenue VS EstimatesURGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
URGN Yearly EPS VS EstimatesURGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

1

4. URGN Valuation Analysis

4.1 Price/Earnings Ratio

  • URGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for URGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
URGN Price Earnings VS Forward Price EarningsURGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
URGN Per share dataURGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as URGN's earnings are expected to grow with 41.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y54.63%
EPS Next 3Y41.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. URGN Dividend Analysis

5.1 Amount

  • No dividends for URGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

URGN Fundamentals: All Metrics, Ratios and Statistics

UROGEN PHARMA LTD

NASDAQ:URGN (4/24/2026, 8:12:35 PM)

After market: 24.11 0 (0%)

24.11

-0.2 (-0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)05-07
Inst Owners91.87%
Inst Owner Change0.66%
Ins Owners2.02%
Ins Owner Change0.26%
Market Cap1.17B
Revenue(TTM)109.79M
Net Income(TTM)-153.49M
Analysts84.29
Price Target36.34 (50.73%)
Short Float %18.16%
Short Ratio10.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.52%
Min EPS beat(2)-5.36%
Max EPS beat(2)2.31%
EPS beat(4)1
Avg EPS beat(4)-9.81%
Min EPS beat(4)-23.47%
Max EPS beat(4)2.31%
EPS beat(8)2
Avg EPS beat(8)-3.9%
EPS beat(12)5
Avg EPS beat(12)0.12%
EPS beat(16)8
Avg EPS beat(16)0.71%
Revenue beat(2)0
Avg Revenue beat(2)-12.83%
Min Revenue beat(2)-18.58%
Max Revenue beat(2)-7.08%
Revenue beat(4)1
Avg Revenue beat(4)-8.99%
Min Revenue beat(4)-18.58%
Max Revenue beat(4)2.61%
Revenue beat(8)2
Avg Revenue beat(8)-8.05%
Revenue beat(12)5
Avg Revenue beat(12)-4.92%
Revenue beat(16)5
Avg Revenue beat(16)-6.43%
PT rev (1m)1.06%
PT rev (3m)1.06%
EPS NQ rev (1m)11.25%
EPS NQ rev (3m)4.39%
EPS NY rev (1m)0.35%
EPS NY rev (3m)-62.05%
Revenue NQ rev (1m)-0.4%
Revenue NQ rev (3m)1.43%
Revenue NY rev (1m)0.84%
Revenue NY rev (3m)-2.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.69
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.2
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-3.34
FCFYN/A
OCF(TTM)-3.34
OCFYN/A
SpS2.26
BVpS-2.17
TBVpS-2.17
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -76.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.66%
FCFM N/A
ROA(3y)-59.44%
ROA(5y)-70.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y-0.62%
F-Score1
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 94.14%
Cap/Sales 0.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.01
Quick Ratio 3.65
Altman-Z -5.05
F-Score1
WACC8.09%
ROIC/WACCN/A
Cap/Depr(3y)69.33%
Cap/Depr(5y)65.11%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.5%
EPS Next Y62.75%
EPS Next 2Y54.63%
EPS Next 3Y41.5%
EPS Next 5Y31.85%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y19.48%
Revenue growth 5Y56.22%
Sales Q2Q%54.03%
Revenue Next Year120.41%
Revenue Next 2Y94.11%
Revenue Next 3Y68.59%
Revenue Next 5Y52.71%
EBIT growth 1Y-29.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.15%
EBIT Next 3Y42.07%
EBIT Next 5YN/A
FCF growth 1Y-67.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-67.87%
OCF growth 3YN/A
OCF growth 5YN/A

UROGEN PHARMA LTD / URGN Fundamental Analysis FAQ

What is the fundamental rating for URGN stock?

ChartMill assigns a fundamental rating of 3 / 10 to URGN.


Can you provide the valuation status for UROGEN PHARMA LTD?

ChartMill assigns a valuation rating of 1 / 10 to UROGEN PHARMA LTD (URGN). This can be considered as Overvalued.


What is the profitability of URGN stock?

UROGEN PHARMA LTD (URGN) has a profitability rating of 1 / 10.


Can you provide the financial health for URGN stock?

The financial health rating of UROGEN PHARMA LTD (URGN) is 2 / 10.